18 Apr 2019
MHRA issue a reminder for healthcare professionals administering yellow fever vaccineThis alert highlights two reports of fatal adverse reactions to yellow fever vaccine and the importance of a detailed risk assessment before vaccination
The Medicines and Healthcare products Regulatory Agency (MHRA) has published an alert following two fatal adverse reactions to yellow fever vaccine. This publication reinforces the importance of a detailed individual risk assessment before administering yellow fever vaccine especially for those who may be immunocompromised or aged 60 years and older.
NaTHNaC have been working closely with the MHRA following these two reports of fatal adverse reactions. Measures to minimise risks are being reviewed by an Expert Working Group convened by the Commission on Human Medicines and any updates will be highlighted in due course.
- MHRA: Yellow fever vaccine (Stamaril) and fatal adverse reactions: extreme caution needed in people who may be immunosuppressed and those 60 years and older
- NaTHNaC Yellow Fever Zone
- NaTHNaC Training Portal
- Managing your Yellow Fever Vaccination Centre
- Yellow Fever Vaccine Centre Best Practice Checklist